Clinical trials: Glaucoma, completed
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension
To investigate the dose-response relationship of DE-104 ophthalmic solution in lowering intraocular pressure (IOP) in subjects with Primary Open-Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT00657579
- Testing
- DE-104 ophthalmic solution, low concentration, DE-104 ophthalmic solution, medium concentration, DE-104 ophthalmic solution, high concentration
- Where
- Japan
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open Angle Glaucoma (POAG), Istent Inject W
Trabecular Microbypass IStent in Patients with Glaucoma
The goal of this clinical trial is to assess the safety and efficacy of phacoemulsification combined with one trabecular micro-bypass stent implantation (phaco-iStent) versus phacoemulsification alone in a Taiwanese population…
- Conditions
- Primary Open Angle Glaucoma (POAG), Istent Inject W, Normal Tension Glaucoma (NTG)
- Trial name
- NCT06630546
- Testing
- first generation iStent (Glaukos, San Clemente, CA, USA) insertion, phacoemulsification
- Where
- Taiwan
- Volunteers
- 71 people
- Sponsor
- Yu-Ting Tsao
Open-Angle Glaucoma, Ocular Hypertension
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70
To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.
- Trial name
- NCT00047541
- Testing
- Alcon Investigational Agent
- Where
- United States
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as…
- Trial name
- NCT00440141
- Testing
- latanoprost 0.005% eye drops and brimonidine 0.1% eye drops, latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma
Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort
The purpose of this study is to assess the long-term safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100R/L in subjects previously enrolled in Glaukos Study GC-003.
- Trial name
- NCT01836042
- Where
- 26 sites in United States
- Volunteers
- 108 people
- Sponsor
- Glaukos Corporation
Glaucoma, Ocular Hypertension
Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension
This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension
- Trial name
- NCT00652483
- Testing
- Brimonidine ophthalmic solution 0.1%, Brimonidine ophthalmic solution 0.2%
- Where
- United States
- Volunteers
- 433 people
- Sponsor
- Allergan
Glaucoma
Heidelberg Edge Perimetry (HEP) Detecting Glaucomatous Visual Field Defects
The purpose of this study is to compare standard automated perimetry (SAP) using the Heidelberg Edge Perimeter (HEP) to the Octopus Visual Field (OVF) analyzer and determine test-retest reliability of both parameters in detecting…
- Trial name
- HEP (NCT02526654)
- Testing
- Heidelberg Edge Perimeter, Octopus Visual Field, Optical Coherence Tomography
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Wills Eye
Open Angle Glaucoma, Ocular Hypertension
A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension
- Trial name
- NCT02129673
- Testing
- VS101 Insert Dose A, VS101 Insert Dose B, VS101 Insert Dose C
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- ViSci Ltd.
Glaucoma
Greek Physicians Perceptions Regarding Generics Prescribing in Glaucoma
This attempts to investigate the perceptions of Greek Ophthalmologists regarding generics prescription in glaucoma by means of a structured questionnaire.
- Trial name
- NCT01855802
- Where
- Greece
- Volunteers
- 70 people
- Sponsor
- Democritus University of Thrace
Glaucoma
Sleep at 30 Degrees in Glaucoma
This study is designed to investigate the effect of body posture (particularly when sleeping) on the pressure in the eye. The effect of body posture on progressive glaucoma (glaucoma where a significant change i.e.
- Trial name
- NCT00802061
- Testing
- Sleeping position in glaucoma patient
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Open Angle Glaucoma or Ocular Hypertension
A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study
The purposes of this study are to evaluate the long-term safety and intraocular pressure-lowering efficacy of DE-117 ophthalmic solution monotherapy and concomitant use of DE-117 ophthalmic solution with timolol ophthalmic…
- Trial name
- NCT02822729
- Testing
- DE-117 ophthalmic solution, Timolol ophthalmic solution
- Where
- Japan
- Volunteers
- 125 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Glaucoma, Ocular Surface Disease
24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy
The study investigated the 24-hour efficacy and ocular surface health with preservative-free tafluprost and a combined preservative-free regimen (tafluprost and dorzolamide/timolol fixed combination) in open-angle glaucoma…
- Trial name
- NCT02802137
- Testing
- tafluprost, tafluprost and dorzolamide/timolol
- Volunteers
- 43 people
- Sponsor
- Aristotle University Of Thessaloniki
Glaucoma, Ocular Hypertension
Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension
This study evaluates the safety and efficacy of different formulations of bimatoprost ophthalmic solution compared with Bimatoprost 0.03% once-daily in patients with glaucoma or ocular hypertension.
- Trial name
- NCT00652496
- Testing
- Bimatoprost 0.01% ophthalmic solution, Bimatoprost 0.015% formulation 1 ophthalmic solution, Bimatoprost 0.015% formulation 2 ophthalmic solution
- Where
- United States
- Volunteers
- 249 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
The objective of this parallel group study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.
- Conditions
- Glaucoma, Ocular Hypertension, Eye Disease
- Trial name
- NCT02136940
- Testing
- AMA0076
- Where
- 9 sites in United States
- Volunteers
- 103 people
- Sponsor
- Amakem, NV
Ocular Hypertension, Open Angle Glaucoma
CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension
To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT04360174
- Testing
- OTX-TIC
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Ocular Therapeutix, Inc.
Glaucoma
Polymorphisms in the Human Matrix Metalloproteinase Genes MMP1, MMP3, and MMP9: Genetic Risk Factors of Primary Open Angle Glaucoma?
Matrix metalloproteinases (MMPs) fulfill diverse important molecular functions and play pivotal roles in development, tissue morphogenesis, repair, aging, and inflammatory processes.
- Trial name
- NCT00312403
- Testing
- Blood Sample
- Where
- Austria
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Glaucoma, Ocular Hypertension
A Study to Evaluate the Effectiveness of Cosopt® as First Line Therapy (MK-0507A-153)
Evaluate the effectiveness of dorzolamide-timolol (Cosopt®) as first line therapy in reducing intraocular pressure in patients with untreated Open angle glaucoma (OAG) or Ocular hypertension (OH).
- Trial name
- NCT00546286
- Testing
- dorzolamide hydrochloride (+) timolol maleate, Comparator: dorzolamide HCl/timolol maleate + prostaglandin
- Volunteers
- 170 people
- Sponsor
- Merck Sharp & Dohme LLC
Glaucoma, Intraocular Pressure
Intraocular Pressure Fluctuation in Patients With Glaucoma and in Healthy Patients During Standard Yoga Positions
The purpose of the study is to investigate the IOP difference between normal and glaucomatous eyes using standard ophthalmic tonometry devices while subjects are performing different standard yoga asanas.
- Trial name
- NCT01915680
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Robert Ritch, MD, LLC.
Obstructive Sleep Apnoea, Open Angle Glaucoma
Prevalence of Obstructive Sleep Apnoea in Glaucoma
This study aims to investigate a potential link between Obstructive Sleep Apnoea (OSA) and Open Angle Glaucoma (OAG); initially by determining whether the prevalence of OSA is higher in patients with OAG in comparison to people…
- Trial name
- POSAG (NCT02713152)
- Where
- United Kingdom
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Papworth Hospital NHS Foundation Trust
Glaucoma, Open-Angle
Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient Target Pressures With Bimatoprost 0.03% in Glaucoma
The purpose of this study is to evaluate the range of target IOPs set for glaucoma patients starting monotherapy with bimatoprost and to evaluate patient and physician satisfaction with bimatoprost in "real-world" settings
- Trial name
- NCT00487214
- Volunteers
- 361 people
- Sponsor
- Allergan